Physician profile
Joseph E Kepko
NPI 1326074899
$1,673.99
in general payments reported to CMS, 2019-2025
16 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $260 · 2021: $257 · 2022: $150 · 2023: $141 · 2024: $91.28 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $888.44 | 2019-2025 | Xeomin |
| Allergan, INC. | $169.33 | 2019-2020 | |
| Janssen Biotech, INC. | $120.80 | 2025 | Simponi Aria, Tremfya |
| Abbvie INC. | $76.48 | 2021-2025 | |
| Acerus Pharmaceuticals Corporation | $55.59 | 2022 | |
| Galderma Laboratories, L.P. | $52.69 | 2019-2023 | Dysport |
| Amarin Pharma, INC. | $49.92 | 2021 | |
| Antares Pharma, INC. | $46.62 | 2019-2021 | |
| Aytu Biopharma, INC. | $37.87 | 2020 | |
| Abbott Laboratories | $36.51 | 2022-2023 | Freestyle Libre 3 |
| Cumberland Pharmaceuticals, INC. | $29.65 | 2020-2024 | Kristalose |
| Merck Sharp & Dohme LLC | $28.17 | 2021 | |
| Acella Pharmaceuticals, LLC | $24.60 | 2024 | NP Thyroid 60 |
| Lilly USA, LLC | $23.51 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.67 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kepko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.